argenx SE of the Netherlands continued the expansion of its antibody treatment for autoimmune diseases, Vyvgart (efgartigimod), with regulatory filings for a new formulation of the product in the US, Japan and Europe. Vyvgart is a biologic that was approved by the US Food and Drug Administration in late 2021 and subsequently in the EU and Japan to treat generalised myasthenia gravis (gMG), a chronic autoimmune disease.
